XOCHELLI, Aliki, Panagiotis BALIAKAS, Ioannis KAVAKIOTIS, Andreas AGATHANGELIDIS, Lesley-Ann SUTTON, Eva MINGA, Stavroula NTOUFA, Eugen TAUSCH, Xiao-Jie YAN, Tait SHANAFELT, Karla PLEVOVÁ, Myriam BOUDJOGRA, Davide ROSSI, Zadie DAVIS, Alba NAVARRO, Yorick SANDBERG, Fie Juhl VOJDEMAN, Lydia SCARFO, Niki STAVROYIANNI, Andrey SUDARIKOV, Silvio VERONESE, Tatiana TZENOU, Teodora KARAN-DJURASEVIC, Mark CATHERWOOD, Dirk KIENLE, Maria CHATZOULI, Monica FACCO, Jasmin BAHLO, Christiane POTT, Lone Bredo PEDERSEN, Larry MANSOURI, Karin E. SMEDBY, Charles C. CHU, Veronique GIUDICELLI, Marie-Paule LEFRANC, Panagiotis PANAGIOTIDIS, Gunnar JULIUSSON, Achilles ANAGNOSTOPOULOS, Ioannis VLAHAVAS, Darko ANTIC, Livio TRENTIN, Marco MONTILLO, Carsten NIEMANN, Hartmut DOHNER, Anton W. LANGERAK, Šárka POSPÍŠILOVÁ, Michael HALLEK, Elias CAMPO, Nicholas CHIORAZZI, Nikos MAGLAVERAS, David OSCIER, Gianluca GAIDANO, Diane F. JELINEK, Stephan STILGENBAUER, Ioanna CHOUVARDA, Nikos DARZENTAS, Chrysoula BELESSI, Frederic DAVI, Anastasia HADZIDIMITRIOU, Richard ROSENQUIST, Paolo GHIA and Kostas STAMATOPOULOS. Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clinical cancer research. Philadelphia: AMER ASSOC CANCER RESEARCH, 2017, vol. 23, No 17, p. 5292-5301. ISSN 1078-0432. Available from: https://dx.doi.org/10.1158/1078-0432.CCR-16-3100.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
Authors XOCHELLI, Aliki (752 Sweden), Panagiotis BALIAKAS (752 Sweden), Ioannis KAVAKIOTIS (300 Greece), Andreas AGATHANGELIDIS (380 Italy), Lesley-Ann SUTTON (752 Sweden), Eva MINGA (300 Greece), Stavroula NTOUFA (300 Greece), Eugen TAUSCH (276 Germany), Xiao-Jie YAN (840 United States of America), Tait SHANAFELT (840 United States of America), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), Myriam BOUDJOGRA (250 France), Davide ROSSI (380 Italy), Zadie DAVIS (826 United Kingdom of Great Britain and Northern Ireland), Alba NAVARRO (724 Spain), Yorick SANDBERG (528 Netherlands), Fie Juhl VOJDEMAN (208 Denmark), Lydia SCARFO (380 Italy), Niki STAVROYIANNI (300 Greece), Andrey SUDARIKOV (643 Russian Federation), Silvio VERONESE (380 Italy), Tatiana TZENOU (300 Greece), Teodora KARAN-DJURASEVIC (688 Serbia), Mark CATHERWOOD (826 United Kingdom of Great Britain and Northern Ireland), Dirk KIENLE (276 Germany), Maria CHATZOULI (300 Greece), Monica FACCO (380 Italy), Jasmin BAHLO (276 Germany), Christiane POTT (276 Germany), Lone Bredo PEDERSEN (208 Denmark), Larry MANSOURI (752 Sweden), Karin E. SMEDBY (752 Sweden), Charles C. CHU (840 United States of America), Veronique GIUDICELLI (250 France), Marie-Paule LEFRANC (250 France), Panagiotis PANAGIOTIDIS (300 Greece), Gunnar JULIUSSON (752 Sweden), Achilles ANAGNOSTOPOULOS (300 Greece), Ioannis VLAHAVAS (300 Greece), Darko ANTIC (688 Serbia), Livio TRENTIN (380 Italy), Marco MONTILLO (380 Italy), Carsten NIEMANN (208 Denmark), Hartmut DOHNER (276 Germany), Anton W. LANGERAK (528 Netherlands), Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution), Michael HALLEK (276 Germany), Elias CAMPO (724 Spain), Nicholas CHIORAZZI (840 United States of America), Nikos MAGLAVERAS (300 Greece), David OSCIER (826 United Kingdom of Great Britain and Northern Ireland), Gianluca GAIDANO (380 Italy), Diane F. JELINEK (840 United States of America), Stephan STILGENBAUER (276 Germany), Ioanna CHOUVARDA (300 Greece), Nikos DARZENTAS (300 Greece, belonging to the institution), Chrysoula BELESSI (300 Greece), Frederic DAVI (250 France), Anastasia HADZIDIMITRIOU (752 Sweden), Richard ROSENQUIST (752 Sweden), Paolo GHIA (380 Italy) and Kostas STAMATOPOULOS (752 Sweden).
Edition Clinical cancer research, Philadelphia, AMER ASSOC CANCER RESEARCH, 2017, 1078-0432.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 10.199
RIV identification code RIV/00216224:14740/17:00098220
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1158/1078-0432.CCR-16-3100
UT WoS 000409037300034
Keywords in English B-CELL RECEPTORS; GENE MUTATIONAL STATUS; ANTIGEN RECEPTORS; CD38 EXPRESSION; GENOMIC ABERRATIONS; SEQUENCE-ANALYSIS; I-ANTIGEN; IMMUNOGLOBULIN; ANTIBODIES; DNA
Tags MEDGENET, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 1/3/2018 14:54.
Abstract
Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication. Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes. Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P < 0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively). Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management. (C) 2017 AACR.
Links
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 18/10/2024 07:38